[Comment] Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer
Summary
The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in patients with oligometastatic hormone-sensitive prostate cancer (HSPC).1 By showing that 177Lu-PSMA-617 can significantly delay disease progression while maintaining a favourable safety profile, the BULLSEYE trial expands t…
The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in patients with oligometastatic hormone-sensitive prostate cancer (HSPC).1 By showing that 177Lu-PSMA-617 can significantly delay disease progression while maintaining a favourable safety profile, the BULLSEYE trial expands the therapeutic horizon of PSMA-targeted radioligand therapy beyond its established role in metastatic castration-resistant prostate cancer (mCRPC).